Facebook Instagram Twitter Linkedin Youtube
REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne
April 12, 2023
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Mutations Amenable to Exon 44 Skipping
April 24, 2023

NS Pharma Announces FDA Clearance to Initiate Phase II Study for NS-089/NCNP-02, an Exon 44 Skipping Candidate for the Treatment of Duchenne

April 18, 2023

On Friday, April 14, 2023, NS Pharma announced that the U.S. Food & Drug Administration (FDA) has agreed to the planned Phase II study of NS-089/NCNP02 for Duchenne muscular dystrophy.

Please read the full update on their shared press release.

Jett Foundation, Inc.
65 Cordage Park Circle
Suite 130 | Plymouth, MA 02360
781-585-5566 | info@jettfoundation.org

Gold Transparency 2022 Candid. Logo
Sitemap
© 2023 All rights reserved. Powered by Getfused

Support Jett Foundation

Donate Today
Jett Foundation, Inc. is a 501(c)3 registered tax-exempt nonprofit organization. Our Federal Tax ID is 04-3563445.

Stay Connected With Us

Sign up to receive our newsletter and updates.
Required fields are denoted with an asterisk (*)





    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Experience the magic of camp promise

    Complete applications due April 3, 2023.
    Apply Now